Egypt Multiple Myeloma Research Review Issue 6

In this issue:
  -  Sustained MRD negativity in newly diagnosed MM: impact of daratumumab
  -  Prognostic value of MRD negativity in MM
  -  Predicting early severe infections in newly diagnosed MM
  -  Infectious complications in relapsed/refractory MM after BCMA CAR T-cell therapy
  -  QOL, psychological distress and prognostic perceptions in MM
  -  Neurotoxicity in MM treated with ciltacabtagene autoleucel
  -  Ciltacabtagene autoleucel vs. conventional treatment for relapsed/refractory MM
  -  Adding isatuximab to pomalidomide and dexamethasone in relapsed/refractory MM
  -  Adding melflufen or pomalidomide to dexamethasone for lenalidomide-refractory MM
  -  Long-term outcomes of standard MM therapy in the real world

Download PDF Subscribe